Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FLGT
HoldHot AirFulgent Genetics, Inc. · Healthcare · United States · $540M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing and genomic data solutions across inherited diseases, cancer, and infectious diseases. The company's competitive moat is its proprietary, high-throughput next-generation sequencing (NGS) platform and advanced bioinformatics, enabling rapid, cost-effective, and highly accurate diagnostic testing. Fulgent leverages its scalable technology to offer an extensive test menu and cater to a broad clinical and research market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 619.0M | 289.2M | 283.5M | 322.7M | -19.5% | 323.9M | 331.7M | 382.7M | 8.9% |
| EPS | 4.76 | -5.63 | -1.41 | -1.97 | — | -2.83 | -2.27 | -1.38 | — |
| Shares | 29.4M | 29.7M | 30.8M | 31.1M | +5.6% | 27.5M | — | — | — |
| Debt | 38.9M | 15.3M | 8.5M | 7.7M | -41.8% | 9.6M | — | — | — |
| Equity | 1.3B | 1.1B | 1.1B | 1.1B | -4.2% | — | — | — | — |
| Op CF | 253.5M | 27.0M | 21.1M | -101.6M | -71.2% | -83.7M | — | — | — |
| Inv CF | -261.3M | 38.9M | -58.4M | 111.4M | — | — | — | — | — |
| Fin CF | -77.1M | -47.8M | -4.8M | -14.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FLGT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FLGT | Fulgent Genetics, Inc.(you) | $540M | 45 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| OPK | OPKO Health, Inc. | $1.1B | 38 | Hold |
| BDSX | Biodesix, Inc. | $283M | 29 | Sell |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
| XGN | Exagen Inc. | $179M | 28 | Sell |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| FRNM | Freenome, Inc. | $1.6B | 18 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%